endpts.com·Jun 3, 2026
Alnylam Pharmaceuticals has entered its first AI-focused discovery deal with the Silicon Valley startup Inceptive, committing $30 million upfront to enhance its RNA research and development efforts.
Alnylam Pharmaceuticals' $30 million upfront investment in a discovery-focused AI partnership with Inceptive highlights a strategic move to leverage AI for enhancing RNA research and development. For professionals interested in AI-driven drug discovery, this deal serves as a significant signal of AI's growing role in biopharma R&D and could be a model for similar partnerships aimed at accelerating drug discovery processes.